Recursion’s small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5.
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response
Vistim Labs Closes First Round of Funding
Respective leaders in healthcare innovation and RNA diagnostics team up to identify patients who will benefit from immunotherapy
NexEos Bio today announced that Dawn Rubel has joined the Company as President, Research and Development.
PROPRIETARY ION SOURCE AND BEAM TECHNOLOGY CAPABLE OF PRODUCING APPROXIMATELY 10 TIMES THE CURRENT GLOBAL SUPPLY OF ASTATINE-211
Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies
Intermountain Health announced the launch of Culmination Bio, a biotech company developing an exclusive, anonymized, and de-identified intelligence platform.
BioUtah continues to monitor issues of importance to our industry and engage with legislators on Utah’s Capitol Hill.
R-Zero’s UV-C Technology Improves Indoor Air Quality for Millions of People; Reduces Reliance on HVAC Systems and Chemicals that Harm Environment
Facility will produce high-performance ceramic armor products for personnel, aircraft, and vehicles
SINTX Technologies Announces Closing of $12.0 Million Public Offering